INTRODUCTION

Inflammation, a normal host response against noxious stimuli, may be acute or chronic. Acute inflammation comprises short-term responses to pro-inflammatory injuries, which involve vasodilation, increased capillary permeability and neutrophil migration from the blood to the inflammatory site. In turn, chronic inflammation is linked with long-standing diseases, like osteoarthritis, atherosclerosis and cancer, among others. 1,2

The characteristic pattern of the inflammatory response involves high levels of arachidonic acid (AA) produced by the action of phospholipase A2 on membrane phospholipids, which is then metabolized through the cyclooxygenase (COX) and lipooxygenase (LOX) pathways to produce prostaglandins (PG), thromboxanes, prostacyclins, and inflammatory leukotrienes (LT). 3

Non-selective non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors, widely prescribed worldwide, are quite effective to treat inflammation and associated pain. Since the incidence of diseases associated to chronic inflammation increases with age, the use of NSAIDs should raise in accordance to the increased life expectancy. 1,5 Nevertheless, NSAIDs cause adverse side effects associated with COX-1 inhibition, like gastric damage and bronchospasm, and cardiovascular effects related with COX-2 inhibition, so that their use in the elderly should be monitored. 6-9 NSAIDs and COX-2 inhibitors display their anti-inflammatory effects through the inhibition of COX pathway, which curtails the production of gastroprotective PG and displace the AA metabolism towards the LOX pathway, thus increasing the synthesis of pro-inflammatory and gastrotoxic LT, so that the walls of NSAID-induced gastric ulcers have high concentrations of LTB4, which attract leukocytes to the stomach and contribute to cause the ulceration, 10 thus enhancing the gastrotoxicity due to the PG deficit. 4

This scenario has supported the search of effective anti-inflammatory substances that may be better tolerated than NSAIDs, as those able to inhibit both COX and 5-LOX enzymes. These dual acting anti-inflammatory drugs may cut PG synthesis, which supports an anti-inflammatory effect, and to prevent the switch to the increased LT production through the concomitant inhibition of 5-LOX, thus reducing the occurrence of adverse side effects. Despite this potential advantage, few dual anti-inflammatory drugs have been introduced in the clinical practice. 11-14

Lyprinol, trade mark of a lipid extract from green-lipped mussel (Perna canaliculus), produces a dual inhibition of COX and 5-LOX enzymes. Lyprinol has been used for the symptomatic relief of some inflammatory conditions without causing the iatrogenic effects of NSAIDs. 15-18 Experimental models of collagen-induced arthritis 17 and bowel-induced inflammatory colitis 19 have proven the anti-inflammatory efficacy of Lyprinol in vivo, although this effect has not been supported by randomized, double-blind, placebo-controlled trials and comparative studies. 15

D-002, a mixture of high molecular weight aliphatic alcohols (C26, C24, C28, C30, C32, C34) purified from beeswax, has been shown to produce anti-inflammatory effects in experimental models, 20-22 and to inhibit COX and 5-LOX inflammatory effects in pleurisy in rats.
enzyme activities, which supports its anti-inflammatory effects devoid of concomitant gastrotoxicity. Instead, D-002 exhibits a gastroprotective action through a mechanism that involves the increase of gastric mucus secretion and the reduction of oxidative stress in the gastric mucosa.

In light of these issues, this study compared the anti-inflammatory effects of D-002 and Lyprinol in rats with carrageenan-induced pleurisy, a classical model of acute inflammation.

MATERIALS AND METHODS

Animals
Male Sprague Dawley rats (200-250 g) were purchased to the National Center for Laboratory Animal Production (CENPALAB, Havana, Cuba) and adapted for 7 days to the following experimental conditions: temperature (22-23°C), relative humidity (55-60%) and 12 hours dark/light cycles. Food and water were freely supplied. The study was conducted in accordance with Cuban guidelines for the care of laboratory animals and the Cuban Code of Good Laboratory Practice (GLP). An independent ethic board approved the study protocol and the use of the animals for this study.

Administration and dosage
The D-002 batch used in the study was supplied by the Plants of Natural Products (National Centre for Scientific Research, Havana City, Cuba). The batch composition, assessed with a validated gas chromatographic method, was the following: 1-tetrasacanol (7.1%), 1-hexasacanol (11.2%), 1-oktosacanol (13.8%), 1-triascontanol (31.4 %), 1-dotriascontanol (22.1%) and 1-tetraotiascontanol (2.5%). Purity (total content of these alcohols) was 88.1%.

The lipid extract from green-lipped mussel (Perna canaliculus) contains long-chain omega-3 polyunsaturated fatty acids (PUFAs) like eicosapentaenoic acid (14-20%), docosahexaenoic acid (11-17%) and other PUFA, palmitic acid 15-17%, cholesterol (about 30%) and sterols, sterol esters, triglycerides and polar lipids, as well. Lyprinol soft-gel capsules (Blackmores, Australia, batch: 252918) used for the experiments contained 50 mg of the lipid extract from green-lipped mussel (Perna canaliculus) diluted in olive oil and Vitamin E. The content of the capsules was directly drawn with a syringe and used in the experiments.

D-002 and Lyprinol were suspended in 2% Tween 65/water, respectively, while aspirin (from the Cuban Pharmaceutical Industry, Havana, Cuba) was dissolved in acacia gum/water vehicle (10 mg/mL). All treatments were administered acutely by gastric gavage (5mL/kg).

Rats were randomized into eleven groups (8 rats per group): a negative control injected with saline dissolution in the pleural cavity and ten carrageenan-injected groups: one positive control (treated orally with the Tween65/water vehicle), four groups treated with D-002 (25, 50, 100 and 200 mg/kg), four with Lyprinol (25, 50, 100 and 200 mg/kg) and other with aspirin (100 mg/kg), the reference drug.

Induction of carrageenan-induced pleurisy (oedema)
Carrageenan-induced pleurisy was provoked 1 hour after the oral treatment. In brief, rats were anesthetized with sodium thiopental (40 mg/kg). Pleurisy was induced by intrapleural injection of 300 µL of 1% (w/v) carrageenan in saline dissolution. A specially adapted needle was introduced into the right side of the thoracic cavity of rats to inject the carrageenan suspension, and an equal volume of sterile saline was injected into the negative controls. Five hours later, under an overdose of sodium thiopental, rats were sacrificed, their thoracic cavities were opened and pleural exudates were collected, homogenized in 1 mL of 3.15% sodium citrate and measured. Blood-contaminated exudates were discarded. The percentage of oedema inhibition was calculated as follows: Inhibition (%) = 100 - (TV/CV) x 100 (%), where TV and CV represent the volume of pleural exudates in treated and control rats, respectively.

The significant reduction of the exudate volume as compared to the positive control groups was the primary efficacy variable of this study.

Assessment of myeloperoxidase (MPO) enzyme activity
MPO activity in the pleural cavity was measured in accordance with the Worthington enzyme manual. Samples were sonicated for 10 seconds, freezing and thawing at 20 to 30 °C three times, and centrifuged at 12 000 rpm for 25 minutes at 4 °C. Then, 250 µL of the supernatant were mixed with 625 µL of 50 mmol/L phosphate buffer (pH 6) containing 0.167 mg/mL O-dianisidine dihydrochloride and 125 µL of 0.0005% hydrogen peroxide. The absorbance changes at 460 nm were measured for two minutes in a spectrophotometer. MPO activity data was expressed as units/g of tissue (U/g tissue). One unit of MPO activity was defined as that able to degrade 1 µmol of H₂O₂ per minute at 25 °C and was quantified as follows: U/g tissue = ∆A min. x FV/8.3 x SV x 10, wherein ∆A min represents the absorbance variation, FV the final volume in the cuvete and SV the volume of the added sample.

Total proteins
The concentration of total proteins was determinate by a modification of the Lowry method.

Statistical analyses
Comparisons among the groups were done with the Kruskal-Wallis test, paired comparisons between treated and control groups with the Mann-Whitney U test. Statistical significance was chosen for α = 0.05. Data were processed with the Statistics Software for Windows (Release 6.1 Stat Soft Inc, Tulsa OK, USA). Dose/effect relationship was assessed by using lineal regression and correlation test using a Primer of Biostatistics program.
RESULTS AND DISCUSSION

Table 1 summarizes the effects on the formation of pleural exudates. Carrageenan intrapleural injection increased the volumes of the pleural exudates of the positive controls as compared with those of the negative control group. This effect was significantly, dose-dependently (ρ = 0.049, r = 0.951) and moderately (≤ 15 - 34%) attenuated by D-002 (25-200 mg/kg) as compared to the positive control group. The decrease produced led to modify the protein content of the groups (Mann Whitney U test).

Positive controls exhibited greater values of MPO activity and protein concentrations in the pleural exudates than the negative controls (Table 2). D-002 (25-200 mg/kg) significantly inhibited MPO activity (≥15 – 34%) as compared to the positive control, in a manner that the inhibitions enhanced with the doses (ρ = 0.022, r = 0.978), but the ceiling effect was not found. In turn, Lyprinol (25-200 mg/kg) significantly inhibited MPO activity (≥16 – 38%) versus the positive control, but once again the maximal effect was not reached. The effects of D-002 and Lyprinol were statistically similar. Both treatments, however, failed to modify the protein content of the pleural exudates.

Table 1: Effects of D-002 and Lyprinol on the volume of pleural exudates

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Doses (mg/kg)</th>
<th>Exudate volume (ml)</th>
<th>I (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative control</td>
<td>___</td>
<td>0.11 ± 0.05***</td>
<td>___</td>
</tr>
<tr>
<td>Positive control</td>
<td>___</td>
<td>1.46 ± 0.11</td>
<td>___</td>
</tr>
<tr>
<td>D-002</td>
<td>25</td>
<td>1.26 ± 0.09</td>
<td>14.8</td>
</tr>
<tr>
<td>D-002</td>
<td>50</td>
<td>1.10 ± 0.05*</td>
<td>26.6</td>
</tr>
<tr>
<td>D-002</td>
<td>100</td>
<td>1.05 ± 0.07*</td>
<td>30.3</td>
</tr>
<tr>
<td>D-002</td>
<td>200</td>
<td>1.00 ± 0.06*</td>
<td>34.0</td>
</tr>
<tr>
<td>Lyprinol</td>
<td>25</td>
<td>1.26 ± 0.13</td>
<td>14.8</td>
</tr>
<tr>
<td>Lyprinol</td>
<td>50</td>
<td>1.22 ± 0.10</td>
<td>17.7</td>
</tr>
<tr>
<td>Lyprinol</td>
<td>100</td>
<td>1.02 ± 0.08*</td>
<td>32.5</td>
</tr>
<tr>
<td>Lyprinol</td>
<td>200</td>
<td>1.05 ± 0.26*</td>
<td>30.3</td>
</tr>
<tr>
<td>Aspirin</td>
<td>100</td>
<td>0.58 ± 0.08**++</td>
<td>65.2</td>
</tr>
</tbody>
</table>

I (%): inhibition percent; *p<0.05, **p<0.01 ***p<0.001 Comparison with the positive control; ++p< 0.01 Comparisons with D-002 and Lyprinol groups (Mann Whitney U test)

Table 2: Effects of D-002 and Lyprinol on myeloperoxidase (MPO) and protein concentrations in pleural exudates

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Doses (mg/kg)</th>
<th>MPO (U/g tissue)</th>
<th>I (%)</th>
<th>Total protein (mg/mL)</th>
<th>I (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative control</td>
<td>___</td>
<td>2.44 ± 1.02**</td>
<td>___</td>
<td>7.49 ± 1.20***</td>
<td>___</td>
</tr>
<tr>
<td>Positive control</td>
<td>___</td>
<td>66.56 ± 1.45</td>
<td>___</td>
<td>23.33 ± 0.78</td>
<td>___</td>
</tr>
<tr>
<td>D-002</td>
<td>25</td>
<td>56.92 ± 1.37**</td>
<td>15.0</td>
<td>22.50 ± 1.30</td>
<td>5.2</td>
</tr>
<tr>
<td>D-002</td>
<td>50</td>
<td>53.79 ± 0.92***</td>
<td>19.9</td>
<td>22.21 ± 0.82</td>
<td>7.1</td>
</tr>
<tr>
<td>D-002</td>
<td>100</td>
<td>46.82 ± 1.26***</td>
<td>30.8</td>
<td>22.25 ± 1.03</td>
<td>6.8</td>
</tr>
<tr>
<td>D-002</td>
<td>200</td>
<td>44.99 ± 1.09***</td>
<td>33.6</td>
<td>22.10 ± 0.78</td>
<td>7.8</td>
</tr>
<tr>
<td>Lyprinol</td>
<td>25</td>
<td>56.50 ± 1.38***</td>
<td>15.7</td>
<td>22.42 ± 1.26</td>
<td>5.7</td>
</tr>
<tr>
<td>Lyprinol</td>
<td>50</td>
<td>52.61 ± 1.04***</td>
<td>21.8</td>
<td>22.65 ± 0.99</td>
<td>4.3</td>
</tr>
<tr>
<td>Lyprinol</td>
<td>100</td>
<td>46.77 ± 2.43**</td>
<td>30.9</td>
<td>22.41 ± 0.92</td>
<td>5.8</td>
</tr>
<tr>
<td>Lyprinol</td>
<td>200</td>
<td>41.87 ± 1.93***</td>
<td>38.5</td>
<td>22.41 ± 1.40</td>
<td>5.8</td>
</tr>
<tr>
<td>Aspirin</td>
<td>100</td>
<td>40.58 ± 3.66**</td>
<td>40.5</td>
<td>17.38 ± 0.60**</td>
<td>38.0</td>
</tr>
</tbody>
</table>

I (%): inhibition percent; **p<0.01 ***p<0.001 Comparison with positive control (Mann Whitney U test)
Aspirin (100 mg/kg) significantly and moderately inhibited MPO activity (40.5%) and reduced the protein content (38.0%) of the pleural exudates.

This study demonstrates that oral treatment with D-002 and Lyprinol produces similar anti-edema effects in rats with carrageenan-induced pleurisy, a classical model of acute inflammation.

The intrapleural administration of carrageenan, a high-molecular-weight sulphated polysaccharide, leads to pleurisy, an inflammatory process characterized by an immediate recruitment of polymorphonuclear cells (PMN) and protein-rich fluid accumulation. In our study, carrageenan produced a marked oedema and increased the MPO activity and the protein content of the pleural exudates as compared to the negative controls, and all the carrageenan-induced changes were inhibited by aspirin, the reference drug, in agreement with the classical features reported for this model, all of which confirms validity to the results obtained in our experimental conditions.

In our experiment, a significant and dose dependent reduction of the pleural exudate volume and MPO activity were noted with both treatments. In addition to be the first head to head comparison of the in vivo effects of D-002 and Lyprinol in an experimental model of inflammation, this study reports, for the first time, the effects of Lyprinol on this model, which were consistent with its mode of action. On the other side, our results confirm the efficacy of D-002 (50, 100 and 200 mg/kg) on this model, in agreement with early reports, but also includes the search of its effects on other targets (MPO activity and protein concentrations in pleural exudates), not tested before in this model. Nevertheless, evidences of the inhibitory effects of D-002 on MPO activity have been reported in other models of inflammation.

These the potential anti-inflammatory effects of high molecular weight alcohols have been explored by other authors. In line with our data, a study found that the intraperitoneal injection of octacosanol (1 and 10 mg/kg) (one of the main components of D-002) extracted from the leaves of Sabicea grisea displayed anti-inflammatory effects in the carrageenan-induced pleurisy. Octacosanol reduced the influx of total leukocytes into the pleural cavity triggered by carrageenan due to the inhibition of neutrophils recruitment, without alter mononuclear cells migration. The mechanism responsible for the anti-inflammatory effects of the octacosanol was assumed to be associated, at least partly, with the inhibition of α2-adrennergic transmission and pathways dependent on pro-inflammatory cytokines.

Aspirin (100 mg/kg) inhibited all changes induced by carrageenan and was more effective than D-002 and Lyprinol for reducing oedema formation and protein concentrations in the exudates, this last variable unaffected by D-002 or Lyprinol. These results should not be surprising. Aspirin is a potent and irreversible COX inhibitor that acts on both COX-1 and COX-2, with a greater affinity for the former. In turn, D-002 and Lyprinol17, 19, 23 are dual COX/5-LOX inhibitors, more effective on 5-LOX than on COX enzyme activity. The increased protein content in the exudates induced by carrageenan depends mainly of the increase in vascular permeability, which is highly dependent of COX-1, so the superior efficacy of aspirin is logical. In addition, recent data support that some lipoxins, lipid mediators that play a key role in the resolution of inflammation, are triggered by aspirin and exert a relevant role in the acute anti-edematogenic action of aspirin in the carrageenan-induced pleurisy.

This study was not undertaken to reveal the mechanism(s) whereby D-002 and Lyprinol are effective on this model. Otherwise, based on the fact that both substances inhibit 5-LOX and COX activities, we assumed and demonstrate that the anti-oedema effects of D-002 and Lyprinol on this model were similar.

The fact that all treatments displayed similar effects on MPO activity, a good indicator of leucocyte recruitment, suggests that they exert similar influence on this process. The superior efficacy of aspirin on oedema formation, however, clearly evidences that leucocyte recruitment is not the only process involved in the oedema formation, which comprises another targets.

CONCLUSION
This study demonstrates that D-002 and Lyprinol orally administered to rats with carrageenan-induced pleurisy were similarly effective for lowering the oedema and for attenuating the increase of MPO activity without affecting the protein concentrations in the pleural exudates.

REFERENCES


Source of Support: Nil, Conflict of Interest: None.